chevron_leftBack
OraSure Technologies, Inc.
OSUR
As of 24 April 2025, OraSure Technologies, Inc. has a market cap of $232.47M USD, ranking #16368 globally and #2811 in the United States. It ranks #1615 in the Healthcare sector, and #136 in the Medical Instruments & Supplies industry.
Key Stats
Enterprise Value
-$20.69MUSD
Revenue (TTM)
$185.83MUSD
Net Income (TTM)
-$19.5MUSD
Company Profile
warningChart data may be delayed
1d |
1w |
1m |
3m |
6m |
YTD |
1y |
3y |
5y |
1.4%
|
2.9%
|
-13%
|
-23%
|
-27%
|
-17%
|
-44%
|
-54%
|
-80%
|
Upcoming Earnings
Earnings Time
bedtime
After Close
Revenue Estimate
$29.57M
-45% yoy
Markets
Exchange |
Ticker |
Price |
Quotes |
|
OSUR
OraSure Technologies Inc
ISIN: US68554V1089
Shares Out.:
Shares Outstanding:
77.488M1
Shares Float:
74.13M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
3.00 USD
|
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About OraSure Technologies, Inc.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products, specimen collection devices, and other diagnostic products in the United States, Europe, Africa, and internationally. The company’s products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, the company develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
Similar Companies